BioSpace News Archive

There are many factors at play to properly formulate a drug so that it’s released into the body in the most effective and efficient way to achieve clinical effect.

Increasing Awareness, Dispelling Myths, and Helping Patients Find the Right Trials

Around 1.7 million people in Canada live with an untreated, disabling hearing loss.

Non-medical switching is a strategy used to reduce administrative expenses by switching the prescription for a stable patient to a “preferred” or cheaper pharmaceutical drug.

MJH Associates‚ Inc., (MJH) a full-service medical media company, is proud to announce that Healthcare Analytics News™ is becoming Inside Digital Health

“When my daughter was in the hospital, I thought there could be a better way to manage her IV tubes,” said an inventor, from Paramus, N.J., “so I invented the I V TUBE MANAGEMENT SYSTEM.”

Mauna Kea Technologies (Paris:MKEA) (OTCQX:MKEAY) inventor of Cellvizio®, the multidisciplinary probe-based and needle-based confocal laser endomicroscopy (pCLE/nCLE) platform, today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the use of the Cellvizio AQ-Flex™ 19 Confocal Miniprobe

Dupixent showed significant improvement on every primary and secondary endpoint in patients with severe CRSwNP who had failed previous treatment with surgery and/or systemic corticosteroids

Orthofix Medical Inc. reported its financial results for the fourth quarter and fiscal year ended December 31, 2018. For the fourth quarter of 2018, net sales were $121.1 million, earnings per share from continuing operations was $0.46 and adjusted earnings per share from continuing operations was $0.55.

Today the FDA is warning about a safety signal that emerged in a required postmarketing trial of the drug Xeljanz in patients with rheumatoid arthritis.